Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients

Critically ill COVID‐19 patients are at high risk of thromboembolic events despite routine‐dosed low‐molecular‐weight heparin thromboprophylaxis. However, in recent randomized trials increased‐intensity thromboprophylaxis seemed futile and possibly even harmful. In this explorative pharmacokinetic (...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijden, Charlotte D. C. C., ter Heine, Rob, Kooistra, Emma J., Brüggemann, Roger J., Walburgh Schmidt, Jesper W. J., de Grouw, Elke P. L. M., Frenzel, Tim, Pickkers, Peter, Leentjens, Jenneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305530/
https://www.ncbi.nlm.nih.gov/pubmed/34965610
http://dx.doi.org/10.1111/bcp.15208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305530/
https://www.ncbi.nlm.nih.gov/pubmed/34965610
http://dx.doi.org/10.1111/bcp.15208

Ejemplares similares